Meanwhile, in case Novo Nordisk can’t convince regulators of oral semaglutide’s merits first time around, it has a large-scale cardiovascular outcome study called SOUL in preparation that ...
Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback